Bayer AG

Bayer AG maintains a capital structure characterized by significant leverage, with total liabilities of €78.6 billion against total equity of €25.9 billion, resulting in a debt-to-equity ratio of 1.44. The company holds €6.7 billion in cash and equivalents, which is insufficient to cover its €37.4 billion in long-term debt, leading to a negative net cash position. Liquidity is assessed as medium risk, supported by a current ratio of 1.01, indicating minimal short-term buffer. Operating cash flow stands at €5.9 billion, but free cash flow is negative at -€2.2 billion due to capital expenditures of €2.5 billion, reflecting ongoing investment or restructuring costs that pressure cash generation. Profitability metrics are currently negative, with a net income of -€3.6 billion and an operating income of -€1.1 billion on revenues of €45.6 billion. This results in a return on equity of -14.0% and a return on assets of -3.5%, indicating that the company is destroying shareholder value in the current period. The price-to-book ratio is 1.86, while the EV/EBITDA is negative (-73.3), rendering traditional earnings-based valuation multiples ineffective. The negative operating income suggests that gross profit of €26.8 billion is being consumed by high operating expenses, likely including research and development, selling, general, and administrative costs, as well as potential litigation or restructuring charges. Revenue concentration and segment details are not explicitly provided in the available data, preventing a detailed analysis of geographic or product mix exposure. However, the classification as a Pharmaceuticals industry player within the Health Care sector implies a diversified portfolio typical of large-cap healthcare firms. The absence of specific segment data limits the ability to assess concentration risk, but the scale of €45.6 billion in revenue suggests a broad market presence. The company’s activity is unclassified in the detailed activity field, relying on the broader industry codes for context. Growth trajectory analysis is constrained by the absence of historical period data in the input. Without multi-year revenue or net income trends, it is not possible to determine the direction of growth or decline from the provided snapshot alone. The current negative net income represents a significant deviation from typical profitable operations, suggesting a cyclical downturn, one-time charges, or structural challenges. The lack of historical context prevents a comparison of current performance against past trends, leaving the growth narrative incomplete. Risk assessment highlights medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, which is a critical balance sheet weakness. The low dilution risk suggests that the company is not currently issuing significant new shares, which is supported by the identical basic and diluted share counts of 982.4 million. The primary risks appear to be financial, stemming from high leverage and negative profitability, rather than equity dilution. The negative free cash flow further exacerbates the liquidity concern, as the company is not generating sufficient cash from operations to cover its capital needs. Recent events and market sentiment are reflected in analyst estimates, with a mean price target of €50.69 and a median of €52.50, suggesting modest upside from the current market price of €49.00. The mean recommendation is 2.09, indicating a lean towards buy, with 4 strong buys and 12 buys versus 6 holds. This analyst sentiment contrasts with the negative financial performance, possibly reflecting expectations of future turnaround or asset value realization. No specific filing, news, or transcript observations are provided to detail recent corporate actions or strategic shifts.